Pharmafile Logo

Portfolio analysis: Making Go/No-Go decisions to optimise the portfolio

Tuesday 20th March 2018 11:00 EST / 16:00 GMT / 17:00 CEST

Register now: http://bit.ly/2FnXsFx

When a pharma company is either considering acquiring a new agent, or developing one in-house, marketers need to understand the impact on the overall portfolio and decide whether to make a go or no-go decision on that asset.Join US Directors Tom Nolte and Melinda Shorr for this webinar which shows you how market research insights allow you to make confident go/no-go decisions in portfolio planning.

They will address:

Why portfolios need to adapt and change
Success today is not necessarily success tomorrow. Depth and diversification are essential to a strong portfolio – we explore the reasons why you need to actively plan for the future.

Considerations for Go/No-go research design for portfolio planning
We show you how to create an effective market research programme – what stakeholders needs to be involved in the planning process, what questions need to be asked and what methods can be used.

Determining value and magnitude metrics
We discuss the criteria by which additions to a pipeline fit into the key metrics – what value they bring to the portfolio and the size of that opportunity (magnitude). Conversely we will look at what the removal of an asset has on the overall portfolio.

Speed of decision-making
If agents are being developed in-house, evaluations can be made slowly and rigorously. When agents are being acquired, the decision to go or no-go often needs to be made quickly. We discuss the impact on market research design. 
Our presenters will also use a case study to demonstrate how market research insights support better decision-making on new agents in a portfolio.

Question and answer session
Following the presentation there will be a live Q&A where they will address any specific challenges you have encountered or concerns you may have about conducting portfolio analysis studies. We welcome you to submit your questions in advance when you register.

Register now: http://bit.ly/2FnXsFx

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Research Partnership is UK’s fastest growing healthcare market research specialist

The latest league tables for the UK market research industry have just been released and reveal Research Partnership to be the fastest growing healthcare market research specialist for 2014.With turnover...

Emerging Markets: Your Essential Guide

Using our combined knowledge and years of experience of working in these territories, our experts have produced an essential guide to help address some of the core challenges for conducting market...

Free Thinking: From promise to practice: immuno-oncology in action

This white paper explores the global outlook for new immunotherapy products, referencing key opinion leaders and payers to investigate how these products are faring both clinically and financially. Immuno-oncology therapies that...

Exploring the Opportunity For Halal In Healthcare

Published in Medical Marketing & Media November 2015

Case study: Opportunity Assessment for a Rare Disease Product in Emerging Markets

Using in-depth-interviews to determine how to maximise the commercial opportunities in different emerging markets

12 Challenges Big Pharma Faces in China

Published in eyeforpharma 16 November by Rachel Howard

Using mobile “diary” research to capture patient-generated insights in COPD

Our latest case study demonstrates how a mobile app methodology was used to deliver key insights into issues faced by COPD patients

Biosimilars in 2018: EU doctors’ perceptions of RA drug market

Published in pharmaphorum October 2015 by Laurent Chanroux

Webinar: Understanding the Patient Journey in China 2015

Utilising local knowledge and detailed case studies, this webinar examines the likely impact on the patient journey and consider the possible implications for market researchers.

Understanding Patient Willingness to Pay

Published in eyeforpharma 12 October by Rachel Howard